Biodol
- Biotech or pharma, therapeutic R&D
BIODOL THERAPEUTICS is a clinical-stage company developing first-in-class compounds for pain management with a novel mechanism of action that targets a key step in the pathophysiology of pain. The BDT compounds are Negative Allosteric Modulators of the interaction between the FLT3 receptor and the FL cytokine. They can be prescribed as an oral monotherapy for neuropathic pain (Nature Communications, 2018). In combination with opioids, they can treat chronic mixed pain disorders by potentiating opioid analgesia while preventing and reversing opioid tolerance and hyperalgesia, two processes that impair the efficacy of long-term opioid use (Nature Communications, 2024). The most advanced compound, BDT272, is currently in Phase 1.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}